These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 2049735)

  • 1. The possibility of diagnosing small pancreatic cancer (less than 4.0 cm) by measuring various serum tumor markers. A retrospective study.
    Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
    Cancer; 1991 Jul; 68(1):149-52. PubMed ID: 2049735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas.
    Satake K; Takeuchi T
    Pancreas; 1994 Nov; 9(6):720-4. PubMed ID: 7846015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Various tumor markers for small pancreatic cancer with special reference to the present status of pancreatic cancer in Japan and our experience over the past 2 years.
    Satake K; Chung YS; Yokomatsu H; Nakata B; Sawada T; Nishiwaki H; Umeyama K
    Pancreas; 1991 Mar; 6(2):234-41. PubMed ID: 1886892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tumor markers for pancreatic and biliary tract cancer].
    Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
    Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
    Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
    Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.
    Okada K; Kawai M; Tani M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
    J Hepatobiliary Pancreat Sci; 2014 Sep; 21(9):648-53. PubMed ID: 24764208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor markers in pancreatic cancer: a comparative clinical study between CEA, CA 19-9 and CA 50.
    Molina LM; Díez M; Cava MT; Maestro ML; Ortega MD; Mendíz JG; Prego A; De Diego JA; Balibrea JL
    Int J Biol Markers; 1990; 5(3):127-32. PubMed ID: 2286776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
    Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
    Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases.
    Satake K; Kanazawa G; Kho I; Chung Y; Umeyama K
    Am J Gastroenterol; 1985 Aug; 80(8):630-6. PubMed ID: 2411125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Br J Cancer; 1994 Mar; 69(3):562-5. PubMed ID: 8123488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum CA242, CA199, CA125, CEA, and TSGF are Biomarkers for the Efficacy and Prognosis of Cryoablation in Pancreatic Cancer Patients.
    Chen Y; Gao SG; Chen JM; Wang GP; Wang ZF; Zhou B; Jin CH; Yang YT; Feng XS
    Cell Biochem Biophys; 2015 Apr; 71(3):1287-91. PubMed ID: 25486903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
    Haglund C; Lundin J; Kuusela P; Roberts PJ
    Br J Cancer; 1994 Sep; 70(3):487-92. PubMed ID: 8080735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Assay of serum elastase 1 in adenocarcinoma of the pancreas: diagnostic value, compared and combined study with serum CEA and CA 19-9].
    Charneau J; Douay O; Daver A; Boyer J
    Gastroenterol Clin Biol; 1988; 12(6-7):548-52. PubMed ID: 3166429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CA 494--a new tumor marker for the diagnosis of pancreatic cancer.
    Friess H; Büchler M; Auerbach B; Weber A; Malfertheiner P; Hammer K; Madry N; Greiner S; Bosslet K; Beger HG
    Int J Cancer; 1993 Mar; 53(5):759-63. PubMed ID: 8449599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patients.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1992; 12(6B):2309-14. PubMed ID: 1295478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitive serum markers for detecting pancreatic cancer.
    Hayakawa T; Kondo T; Shibata T; Hamano H; Kitagawa M; Sakai Y; Ono H
    Cancer; 1988 May; 61(9):1827-31. PubMed ID: 2451556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of CEA, CA 19-9, CA-50, CA-195, and TATI with special reference to pancreatic disorders.
    Masson P; Pålsson B; Andren-Sandberg A
    Int J Pancreatol; 1991 May; 8(4):333-44. PubMed ID: 1791319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
    Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.